OBJECTIVE
We evaluated whether metabolic syndrome (MetS) is associated with an increased incidence of lower extremity peripheral artery disease (PAD) in community dwelling people free of clinical cardiovascular disease at baseline. We assessed whether higher levels of inflammatory biomarkers may mediate the association of MetS with incident PAD.
METHODS
MetS was defined at baseline as the presence of three or more of the following components: elevated waist circumference, triglycerides >/=150mg/dL, reduced high-density lipoprotein (HDL) cholesterol, blood pressure >/=130/85mmHg or taking blood pressure medication, and fasting glucose >/=100mg/dL and <126mg/dL. People with diabetes were excluded. Incident PAD was defined as a decline in the ankle-brachial index (ABI) from normal (ABI 0.90 –<1.40) at baseline to one of the following outcomes at 3 year follow-up: ABI decline to <0.90 combined with a decline ≥0.15 or medical record confirmed PAD outcome. Multivariable Poisson regression was used to estimate the association between MetS and incident PAD.
RESULTS
Among 4,817 participants without PAD at baseline, 1,382 (29%) had MetS. Adjusting for age, sex, race, smoking, physical activity, low-density lipoprotein cholesterol, baseline ABI, and other confounders, 23/1,382 (1.7%) people with MetS developed PAD vs. 30/3,435 (0.87%) people without MetS (risk ratio=1.78 [95% Confidence Interval (CI), 1.04 to 2.82], P=0.031). Adjusting for C-reactive protein, fibrinogen, or interleukin-6 did not attenuate this association.
CONCLUSION
People free of clinical cardiovascular disease with MetS are at increased risk for PAD. Our findings suggest that this association is not mediated by inflammation.